The latest price target for Rani Therapeutics Hldgs (NASDAQ:RANI) was reported by Canaccord Genuity on February 26, 2025. The analyst firm set a price target for $9.00 expecting RANI to rise to within 12 months (a possible 500.00% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Rani Therapeutics Hldgs (NASDAQ:RANI) was provided by Canaccord Genuity, and Rani Therapeutics Hldgs maintained their buy rating.

There is no last upgrade for Rani Therapeutics Hldgs

There is no last downgrade for Rani Therapeutics Hldgs.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rani Therapeutics Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rani Therapeutics Hldgs was filed on February 26, 2025 so you should expect the next rating to be made available sometime around February 26, 2026.

While ratings are subjective and will change, the latest Rani Therapeutics Hldgs (RANI) rating was a maintained with a price target of $9.00 to $9.00. The current price Rani Therapeutics Hldgs (RANI) is trading at is $1.50, which is out of the analyst’s predicted range.